On a quest to double sales, Akorn snags specialized rival VersaPharm in $440M deal

Specialty generics maker Akorn ($AKRX) has nabbed another niche player. Fresh off the closing of its eye-care-oriented buyout of Hi-Tech Pharmacal ($HITK), the Lake Forest, IL-based drug company has snapped up VersaPharm for $440 million. The deal adds expertise in topical remedies and a near-term pipeline worth an estimated $700 million, Akorn said in a statement.

The acquisition of VersaPharm's parent company VPI Holdings is expected to add up to $100 million to Akorn's annual sales and up to $0.12 in earnings per share, Akorn said. Plus, it's "a highly strategic fit," Akorn CEO Raj Rai said. VersaPharm has a pipeline of more than 20 products, including 11 generics already filed for FDA approval.

"Our acquisition strategy will have resulted in doubling our revenues and product portfolio in a short period of time," Rai said. The deal also diversifies Akorn's slate of products, with treatments for hemophilia and tuberculosis. And VersaPharm's dermatology-focused pipeline helps Akorn beef up in an area where it's already gaining strength.

Last August, Akorn agreed to buy Hi-Tech Pharmacal for $640 million to gain access to its slate of eye drugs as well as its nasal sprays, including a generic version of GlaxoSmithKline's ($GSK) allergy spray Flonase. Like VersaPharm, Hi-Tech also brought along topical ointments. The deal made Akorn the third-biggest player in generic eye drugs.

The deal will be funded with $445 million in short-term debt, provided by JPMorgan Chase Bank. J.P. Morgan Securities was Akorn's financial advisor on the deal, with BMO Capital Markets advising VersaPharm and its private equity investor Tailwind Capital.

- read the Akorn release

Special Reports: Pharma's top 10 M&A deals of 2013 | Hi-Tech Pharmacal - Top 11 Fastest-Growing Generics Companies

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.